A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

• Status: Active, not recruiting
• Trial end date: 2021-11-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation

Criteria

Inclusion Criteria:

• Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis

• Palpable spleen of > 10 cm below the left subcostal margin on physical examination at the screening visit OR

• Palpable splenomegaly of 5 to 10 cm below left subcostal margin on physical exam AND active symptoms of MF at the screening visit as demonstrated by presence of 1 symptom score ≥ 5 or 2 symptom scores ≥ 3 using the Screening Symptom Form

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria:

• Use of experimental drug therapy for myelofibrosis, or any other standard drug (eg, danazol, hydroxyurea, etc) with the exception of ruxolitinib within 6 months of starting study (combination) therapy and/or lack of recovery from all toxicities from previous therapy (except ruxolitinib) to Grade 1 or better

• Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications

• Unwillingness to be transfused with blood components

• Recent history of inadequate bone marrow reserve as demonstrated by the following:

• Platelet count < 50 × 10^9/L in the 4 weeks before screening or platelet transfusion(s) within 8 weeks before screening

• Absolute neutrophil count levels < 0.5 × 10^9/L in the 4 weeks before screening

• Subjects with peripheral blood blast count of > 10% at the screening or baseline hematology assessments

• Subjects who are not willing to receive red blood cell (RBC) transfusions to treat low hemoglobin levels

• Inadequate liver function at screening as demonstrated by the following:

• Direct bilirubin ≥ 2.0 × the upper limit of laboratory normal (ULN). (NOTE:

direct bilirubin will only be determined if total bilirubin is ≥ 2.0 × ULN)

• alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN

• Inadequate renal function at screening as demonstrated by creatinine clearance < 50 mL/min or glomerular filtration rate < 50 mL/min/1.73 m^2